2. Монахов К.Н., Холодилова Н.А. Особенности ведения пациенток с обострением атопического дерматита на фоне беременности. Фарматека. 2018;S1:47–51.

3. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–46. doi: 10.1038/ng1767.

4. McGirtL.Y., BeckL.A. Innate immune defects in atopic dermatitis. J Allergy Clin Immunol. 2006;118:202–8. doi: 10.1016/j.jaci.2006.04.033.

5. Bao L., Zhang H., Chan L.S. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137. doi: 10.4161/jkst.24137.

6. Shi B., Bangayan N.J., Curd E., et al. The skin microbiome is different in pediatric versus adult atopic dermatitis. J Allergy Clin Immunol, 2016;138(4):1233–66. doi: 10.1016/j.jaci.2016.04.053.

7. Seite S., Flores G.E., Henley J.B., et al. Microbiome of affected and unaffected skin of patients with atopic dermatitis before and after emollient treatment. J Drugs Dermatol. 2014;13(11):1365–72.

8. Соколовский Е.В., Монахов К.Н., Холодилова Н.А., Домбровская Д.К. Современные подходы к лечению экземы кистей. Клиническая дерматология и венерология. 2011;9(6):40–3.

9. Wollenberg A., Christen-Zäch S., Taieb A., et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–44. doi: 10.1111/jdv.16892.

10. Возможности системной терапии атопического дерматита селективными иммунодепрессантами: резолюция рабочего совещания экспертов по профилю «дерматология». Педиатрическая фармакология. 2022;19(2):209–11.

11. Bubmann C., Novak N. Systemic therapy of atopic dermatitis. Allergol Sel. 2017;1(1):1–8. doi: 10.5414/ALX01285E.

12. Paller A.S., Bansal A., Simpson E.L. et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020;21(1):119–31. doi: 10.1007/s40257-019-00478-y.

13. Beck L.A., Deleuran M., Bissonnette R., et al. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2022;23:393–408. doi: 10.1007/s40257-022-00685-0.

14. Agache I., Akdis C.A., Akdis M., et al. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: 10.1111/all.14690.

15. Guttman-Yassky E., Teixeira H.D, Simpson E.L., et al. Safety and Efficacy of Upadacitinib Monotherapy in Adolescents and Adults with Moderate-to-severe Atopic Dermatitis: Results From 2 Pivotal, Phase 3, Randomized, Double-blinded, Placebo-controlled Studies (Measure Up 1 and Measure Up 2). Oral presentation at: EADVirtual; Oct 29-31, 2020.D3T03.4B.

16. Reich K., Teixeira H. D., de Bruin-Weller M., et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–81. doi: 10.1016/S0140-6736(21)00589-4.

17. Blauvelt A., Teixeira H.D., Simpson E.L., Antonio, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in AdultsWith Moderate-to-Severe Atopic Dermatitis. A Randomized Clinical Trial. JAMA Dermatol. doi:10.1001/jamadermatol.2021.3023. Published online August 4, 2021.

18. Silverberg J.I., Simpson E.L., Thyssen J.P., et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156(8):863–73. doi: 10.1001/jamadermatol.2020.1406.

19. Reich K., Kabashima K., Peris K., et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156(12):33–1343. doi: 10.1001/jamadermatol.2020.3260.

20.Simpson E.L., Lacour J.P., Spelman L. et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–55. doi: 10.1111/bjd.18898.

21. Dawn M.R., Davis M.D., Aaron M., et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2023;90(2):43–56. doi: 10.1016/j.jaad.2023.08.102.